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Abstract 
Background: Plasma Plasmodium falciparum histidine-rich protein-2 (PfHRP2) is the most accurate biomarker 
for severe malaria, but its measurement by ELISA has been considered too unwieldy to incorporate into clinical 
management.
Methods: Plasma samples covering a wide range of PfHRP2 concentrations were applied to rapid diagnostic tests 
(RDTs). RDTs were read by eye and digital capture, and PfHRP2 concentrations were measured via serial dilution with 
results compared to ELISA readings.
Results: The Paracheck® brand showed the strongest correlation (r2 = 0.963) as well as the lowest inter-observer 
variability (combined kappa across band intensities for three observers = 0.938). Plasma PfHRP2 measurement via 
serial dilution showed minimal bias compared to ELISA and acceptable limits of agreement. Three different dilutions 
of a well characterized set of admission samples from uncomplicated and severe malaria patients studied in a low 
transmission setting gave an area under the receiver operator characteristic curve of 0.844 in terms of identifying 
severe malaria.
Conclusions: These studies show that plasma PfHRP2 can be assessed via a single RDT, with application of a 
plasma dilution of 1:5 or 1:10 providing useful diagnostic information to assist in patient management or clinical trial 
inclusion.
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Background
In regions with medium to high intensity transmission of 
Plasmodium falciparum, diagnosing the cause of severe 
febrile illness is particularly challenging because of the 
high background prevalence of malaria parasitaemia. 
A malaria blood film or rapid diagnostic test (RDT) is 
often the only diagnostic available, but the presence of 
parasites is non-specific and malaria is frequently over-
diagnosed, resulting in failure to consider and treat other 
life-threatening conditions [1]. Approximately a quarter 
of patients thought to have cerebral malaria in fact have 
other diagnoses on post-mortem [2].
Plasma P. falciparum histidine-rich protein-2 
(PfHRP2), a soluble protein produced by sequestered 
parasites responsible for severe disease, provides a reli-
able method to distinguish patients with severe malaria 
from febrile patients with an alternative cause of severe 
illness. Plasma PfHRP2 concentrations define malaria 
severity and prognosis with substantially greater accu-
racy than parasitaemia in African children [3–5] and 
Papua New Guinean adults [6]. In African children with 
coma, plasma PfHRP2 concentrations accurately identi-
fied cerebral malaria defined by post-mortem findings [7] 
or malarial retinopathy [7–9]. In African children meet-
ing criteria for severe malaria, but in the lower third of 
plasma PfHRP2 concentrations (<830  ng/ml), the mor-
tality benefit of artesunate over quinine seen at higher 
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PfHRP2 concentrations was entirely lost, a strong indica-
tion that death was due to other causes [10].
Identification of children with low plasma PfHRP2 lev-
els is likely to benefit both individual patients and health 
systems, indicating the need for additional diagnos-
tic procedures and treatments. Relevant investigations 
include cerebrospinal fluid examination in comatose 
children, blood cultures and imaging. Invasive bacterial 
infection is the most commonly identified alternative 
cause of severe febrile illness [11, 12] but blood culture, 
if available, has low sensitivity (particularly when there 
has been pre-treatment with antibiotics). Treatment of all 
severely ill patients with broad-spectrum antibiotics has 
been recommended [1] and is widely (but not completely) 
practised. However, deciding on the type and duration 
of antibiotics, and the benefit of adjunctive steroids, 
requires some knowledge of the likely cause and site of 
disease; furthermore tuberculous meningitis remains an 
important differential in febrile encephalopathy [13]. At 
a health system level, a knowledge of true incidence rates 
of severe malaria as well as the incidence of non-malarial 
diseases is important for guiding future diagnostic and 
treatment pathways in severe febrile illness, particularly 
as transmission levels fall. In addition, in areas of propa-
gation of viral haemorrhagic fever, the decision to isolate 
at a relatively early stage of clinical management is likely 
to be influenced by knowing the malaria attributable risk. 
Point-of-care measurement of PfHRP2 is also relevant for 
enrollment in clinical trials and other prospective studies 
[14].
Measurement of plasma PfHRP2 has generally been 
undertaken via ELISA, taking several hours and requir-
ing resources that are beyond the majority of laboratories 
in malaria endemic regions. Earlier work described the 
feasibility of using a standard diagnostic RDT to quantify 
plasma PfHRP2 [15]. Here these studies were extended 
by testing a number of RDT brands and quantifying the 
RDT readout both by eye and digital capture, comparing 
results to ELISA measurements and using an established 
reference sample for calibration. Relevant dilutions of 
plasma samples from severe and uncomplicated malaria 
patients in a low transmission setting were then tested to 
define the conditions under which useful assessment of 
plasma PfHRP2 in a high transmission setting might be 
achieved using a single RDT.
Methods
Samples
Characterization of the conditions under which RDTs 
could be applied was undertaken in two phases with 
plasma samples from children recruited into the Teule, 
Tanzania site of the AQUAMAT severe malaria trial 
comparing quinine and artesunate [16] (Fig.  1). The 
performance of the RDT at individual sample dilutions 
to discriminate severe from uncomplicated malaria was 
then examined in plasma samples from non-pregnant 
adults (≥16-year-old) admitted to hospital with slide- or 
RDT-confirmed falciparum malaria and enrolled in pro-
spective studies at Chittagong Medical College Hospital, 
Bangladesh (2011); uncomplicated and severe cases were 
defined using modified World Health Organization cri-
teria [17]. ELISA methods and results and issues related 
to ethical permission for testing these samples have been 
previously described [10, 18].
Choice of RDT
Four RDT kits solely based on PfHRP2 detection were 
studied: Core™ Malaria Pf kit (MAL-190020, Core Diag-
nostics, UK), Paracheck® Pf Device (V.3) (cat. 30301025, 
Orchid Biomedical Systems, India), First Response® 
Malaria Antigen HRP2 kit (cat. I13FRC30, Premier Medi-
cal Corporation Ltd., India) and SD Bioline Malaria Ag 
Pf kit (cat. 05FK50, Standard Diagnostics, Korea). A sin-
gle batch of each RDT was used for all work. All brands 
passed Phase 2 of Round 1–3 of the WHO testing pro-
gramme [19].
Reading of RDTs
The intensity of bands was assessed by digital scan-
ning and visual assessment. Scanning was undertaken 
using a BioRad Gel DocTM XR+, using the Colorimetric 
application optimized for faint bands and capturing the 
maximum intensity of each selected area; on occasions 
small white spots just prior to the reaction line (areas 
that remain dry) rendered the mean value for the band 
an unreliable estimate of band intensity. As well as the 
PfHRP2 line itself, readings were taken from the back-
ground area of the nitrocellulose strip and the positive 
control band. For non-linear regression, this background 
intensity was subtracted from the test band result to pro-
duce a net reading representing the band strength rela-
tive to background.
After application of samples test kits were relabelled 
using a code and assessed by three independent observ-
ers blinded to the identity of each sample. Band intensity 
was graded as 0 (no visible band), 1 (faint line), 2 (faint 
band), 3 (clear band weaker than control) and 4 (clear 
band equivalent to or more intense than positive control).
Given that all tests were undertaken with plasma, it was 
appropriate to reassess the timeframe over which band 
strength remained stable visually and by digital scanning. 
In the first phase of work (testing of neat plasma samples 
on four kits, Fig.  1), visual readings were initially made 
between 20 and 40  min after the assay was performed, 
consistent with product recommendations when apply-
ing whole blood to the kits used. We soon observed 
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that, stored in cool, dark, dry conditions, the strength 
of both control and test bands did not change over days 
or weeks, and digital scans were therefore considered to 
be accurate if taken within 1 month of the original assay. 
At the time of writing inspection of the test kits (which 
have been retained) confirms that visual band strength 
remains unchanged more than 2  years after the assays 
were undertaken.
Statistics
Concentrations of plasma samples were determined by 
serial dilution and triplicate analyses, with the point of 
half-maximal intensity calculated by non-linear regres-
sion in GraphPad Prism with the lower asymptote set to 
zero after subtraction of background intensity. Agree-
ment between visual assessment of concentration and 
ELISA readings was assessed by Bland–Altman analysis. 
Interobserver variability was based on the kappa-statistic.
Results
Dynamic range and selection of RDT for further work
The work was undertaken in three phases (Fig. 1). Initial 
work using ten-fold dilutions of pooled malaria plasma 
obtained from severe malaria patients (at a concentra-
tion of 2500  ng/ml) showed that the dynamic range of 
the Paracheck® RDT kit lay between 25 and 250  ng/ml 
PfHRP2 (data not shown). Fifty neat samples from Teule, 
Tanzania, with plasma HRP concentrations ranging from 
zero to 22,012  ng/ml were applied to each of four kits. 
The PfHRP2 concentration associated with half-maxi-
mal signal in each kit ranged from 36.2 (Paracheck®) to 
75.9 ng/ml (First Response®) (Fig. 2; Table 1).
The digital capture data showed that the strength of 
the band correlated well with the gold standard ELISA 
result for 3 of the 4 kits used, with the closest correlation 
found for the Paracheck® kit (r2 = 0.9627; Fig. 2a). Given 
the similar dynamic ranges of the kits, it is unlikely that 
this was due to the range of concentrations studied, but 
rather the intrinsic properties of the kits.
Results from visual assessment closely agreed with 
scanning (Fig.  2b). Interobserver variability was lowest 
with the Paracheck® (kappa-statistic for the combined 
categories  =  0.938), indicating very good agreement 
across the three observers. Identification of strong test 
bands (category 4) or absent bands (category 0) from 
other bands appeared to be most robust, while defining 
bands of intermediate character (categories 1–3) was 
generally associated with poorer levels of agreement.
Seven samples with relatively high plasma concen-
trations (above 7000  ng/ml) were included in order to 
check for a possible prozone phenomenon, in which band 
intensity drops due to flooding of the test strip with free 
antigen. There was no convincing evidence of any reduc-
tion in signal in these highly concentrated samples for 
any of the kits.
Quantitation of individual samples by dilution
The Paracheck® kit was then used to test the ability of 
an RDT to quantitate plasma PfHRP2 in an independent 
set of 20 clinical samples. Samples underwent half-log 
serial dilutions in PBS producing 1:3.2, 1:10, 1:32, 1:100 
and 1:320 dilutions. The neat sample was also applied if 
the 1:3.2 dilution failed to produce a strong band. These 
dilutions were applied in triplicate to Paracheck® kits 
and digital readings obtained as previously (test band 
and background). A log dilution-signal curve was plot-
ted and the EC50 (dilution required to produce a band 
half as intense as maximal intensity) calculated (Fig. 3a). 
By referencing to a pooled plasma control and using the 
ratio of the dilutions required to reach EC50, it was pos-
sible to calculate the absolute PfHRP2 concentration for 
each sample via RDTs only. A Bland–Altman plot using 
log-transformed data was used to examine agreement 
between the RDT-based method and ELISA. Overall 
Fig. 1 Workflow describing sample numbers and origins, kits and dilutions tested and outcomes analysed
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the agreement was good, with no evidence of bias and 
limits of agreement around three-quarters of a log unit 
(approximately fivefold; Fig. 3b).
Single RDT testing
The final step was to explore the accuracy of visual judg-
ment using a single RDT to discriminate severe from 
uncomplicated malaria in 72 patients admitted with 
malaria in a low transmission setting (Chittagong, Bang-
ladesh). Clinical severity assessment was considered as 
gold standard since incidental malaria in these areas is 
rare. The visually robust cut-off between a strong band 
(category 4) and lower strength bands (0–3) was used, 
with a band clearly weaker than positive control indicat-
ing a low probability of severe malaria. Choice of pos-
sible dilutions was informed by the mid-point of the 
Fig. 2 Comparison of four kits for assessment of plasma HRP2 level using 50 admission samples from the AQUAMAT study based on digital scan-
ning (a) or visual assessment (b)
Table 1 Results of  non-linear regression analysis of  ELISA-measured plasma PfHRP2 concentration vs. digital reading, 
and of interobserver variability assessment for each of four kits
Core™ Paracheck® First Response® SD Bioline
Digital assessment
 Top (reading units) 1867 1796 807.2 1414
 HillSlope 1.408 1.904 7.058 1.453
 EC50 (ng/ml) 63.14 36.25 75.91 66.99
 EC50 (95 % CI) 48.38–82.40 31.69–41.48 49.63–116.1 47.35–94.80
 Goodness of fit (r2) 0.9082 0.9627 0.5661 0.8516
Visual assessment kappa-statistic
 0—no visible band 0.7931 1 0.7785 0.7857
 1—faint line 0.3197 1 0.3262 0.3056
 2—faint band 0.7869 0.7432 0.6019 0.6296
 3—clear band weaker than control 0.7778 0.9187 0.5879 0.6384
 4—band at least as strong as control 1 0.9664 0.5662 0.85
 Combined 0.8602 0.9377 0.5865 0.7198
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dynamic range of the Paracheck® RDT being found at 
approximately 50  ng/ml, with the cut-off between cat-
egories 3 and 4 somewhat higher. In previous work, suit-
able thresholds defining severe malaria (or lack of benefit 
of artesunate) were approximately 1000  ng/ml [7, 10], 
indicating that a dilution of approximately a log order 
of magnitude would be necessary to allow visual inspec-
tion to discriminate clinical state. Fixed dilutions of 1:5, 
1:10 and 1:20 were tested. Three observers assessed 
the results, with the majority result taken for calcula-
tions of sensitivity and specificity. The kappa-statistic 
for assessment of strong compared to weaker bands was 
0.8145 indicating good agreement. As expected, visual 
reading was able to pick out samples with lower PfHRP2 
concentrations (Fig.  4a). Each sample was given a score 
according to the combined results from these three 
tested dilutions: 3, strong band at all three dilutions; 2, 
strong band at 1:10 and 1:5 only; 1, strong band at 1:5 
only and 0, weak band at 1:5. Based on these scores the 
area under a receiver-operator characteristic (AUROC) 
curve for assessing disease state (defined by clinical cri-
teria) was 0.844 (p < 0.0001) (Fig. 4b); the sensitivity and 
specificity for the three individual dilutions used are also 
shown in Fig. 4b.
Discussion
There is still substantial room to refine the diagnosis 
of severe febrile illness in high transmission settings, 
and plasma PfHRP2 holds considerable promise in this 
regard. No other biomarker for cerebral malaria has dem-
onstrated the high positive and negative predictive values 
seen for plasma PfHRP2 [20], and it is already the basis of 
most RDTs used for diagnosis of uncomplicated P. falci-
parum malaria. A PfHRP2-based RDT to define plasma 
levels would allow practical assessment in low-resource 
settings and could be the first field-based test since 
microscopy to provide information on the contribution 
of malaria in severe ill children [20]. The work reported 
here demonstrates conditions under which a single 
malaria RDT can provide semi-quantitative informa-
tion on plasma PfHRP2 levels and hence identify African 
children in whom there is a low probability that severe 
malaria is the cause. Several PfHRP2-based RDTs hold 
potential to be applied to this task, although among the 
brands studied here, the Paracheck® RDT appeared to 
have the tightest correlation with ELISA as well as close 
inter-observer agreement. The measured agreement also 
appeared superior to previous studies of dipstick assess-
ment for this purpose [15].
Fig. 3 a Example dilution-signal plot from a serially diluted sample 
(tested in triplicate, with error bars indicating standard error of the 
mean). b Bland–Altman plot of RDT and ELISA-derived plasma PfHRP2 
concentrations for clinical samples; data are log-transformed
Fig. 4 Relationship between concentration determined by ELISA and RDT based on three dilutions (a) and resulting ROC curve for identification of 
severe malaria (b). Inset to b the sensitivity and specificity based on each of the three sample dilutions are shown
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The area under the receiver operator characteristic 
curve for a single RDT in discriminating severe from 
uncomplicated malaria was found to be 0.844, based on 
admission plasma samples from an established cohort of 
uncomplicated and severe adult malaria patients stud-
ied in a low transmission setting [18] (Bangladesh). In 
these patients malaria was unlikely to be an incidental 
cause of illness; indeed any cases in which severe illness 
was primarily due to another analysis would have led to 
an underestimation of performance. Levels of plasma 
PfHRP2 in the uncomplicated and severe groups appear 
to be comparable to those from children in high trans-
mission settings [7, 18]. However testing on plasma from 
children in high transmissions settings, whose level of 
severity of malaria is established either by post-mortem 
or retinal examination [7], would provide a more defini-
tive measurement of accuracy.
This work used a single batch of the Paracheck® RDT 
for all work. Batch-to-batch variation is a well known 
issue with RDTs, and in long-term studies calibration to 
a reference sample would be indicated, along the same 
lines reported for ELISA methodology [10].
Practical implementation of the test currently requires 
prior separation of plasma from whole blood and, since 
all the RDTs studied showed maximal signal well below a 
threshold relevant to discriminating severe disease, dilu-
tion of plasma before application to the RDT. The ideal 
plasma dilution needs to be linked to the expected pro-
portion of cases that the test is targeted to identify, in this 
case apparent cases of severe malaria in which the true 
cause of illness is another disease. For example, in a group 
of one hundred severely ill patients where this propor-
tion is one quarter (derived from the post-mortem studies 
of Taylor et al. [2]), the presence of weak band at a 1:10 
plasma dilution would identify 21 of the 25 target patients 
in whom the cause of severe illness is not malaria, but 
also mistakenly flag 21 of 75 true severe malaria cases. A 
1:5 dilution would pick up 15 of the target population of 
25, while incorrectly flagging only 6 of the severe malaria 
cases. A lower dilution would hence be more appropriate 
for a setting with relatively lower malaria transmission.
Conclusions
In summary, this work shows that a single RDT can be 
used to obtain useful information on plasma HRP2 con-
centration and hence the underlying cause of severe 
febrile illness. Application in the field would be enhanced 
by engineering a simpler testing approach, for example 
by development of an RDT in which plasma selectively 
enters the nitrocellulose strip at an appropriate concen-
tration. Incorporation into management algorithms holds 
promise to refine the diagnosis of severe febrile illness, a 
common syndrome associated with high mortality.
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